TUBB3 and glioma: We have also previously shown that AG119 is not subject to resistance mechanisms common to other antimicrotubule agents (beta-III tubulin over-expression [25], P-glycoprotein) in tumors such as gliomas, suggesting that this agent may have a therapeutic advantage over current agents [13, 31].